Category:
Prophylactic Biological Products
CAS NO:
608141-41-9
Standard:
In-house Standards,

Apremilast was approved by the United States Food and Drug Administration in 2014 for treatment of adults with active psoriatic arthritis and moderate to severe plaque psoriasis.